MAJORITY OF CANCER PATIENTS WITH COVID-19 HAVE SIMILAR IMMUNE RESPONSE TO PEOPLE WITHOUT CANCER

Most people with cancer who are infected by the novel coronavirus produce antibodies at a rate comparable to the rest of the population—but their ability to do so depends on their type of cancer and the treatments they’ve received, according to a new study by researchers at Montefiore Health System and Albert Einstein College of Medicine. The findings, published online today in Nature Cancer, may lead to better care for cancer patients, who face a heightened risk of dying from COVID-19, and suggests that cancer patients should respond well to COVID-19 vaccines.

Read more

Rutgers Cancer Institute of New Jersey to Present Expansive New Hematology Data at the 62nd ASH Annual Meeting and Exposition

The American Society of Hematology (ASH), is the world’s largest professional society with a focus on the causes and treatment of blood disorders. Experts from Rutgers Cancer Institute of New Jersey will be presenting a variety of key hematology data at the 62nd American Society of Hematology Annual Meeting. This includes 22 scheduled presentations, including 10 oral presentations examining several types of blood cancers including leukemia, lymphoma, and myeloma.

Read more

NCCN Meeting on Blood Cancers Will Be Virtual for the First Time

The NCCN Virtual Nursing Forum and Annual Congress: Hematologic Malignancies (#NCCNhem2020) will provide the latest evidence and expert consensus on emerging practices and debates in blood cancer treatment, online October 8-10.

Read more

New High-Throughput Method to Study Gene Splicing at an Unprecedented Scale Reveals New Details About the Process

Genes are like instructions, but with options for building more than one thing. Daniel Larson, senior investigator at the National Cancer Institute, studies this gene “splicing” process, which happens in normal cells and goes awry in blood cancers like leukemia.

Read more

Mutations in donors’ stem cells may cause problems for cancer patients

A new study from Washington University School of Medicine in St. Louis suggests that extremely rare, harmful genetic mutations present in healthy donors’ stem cells — though not causing health problems in the donors — may be passed on to cancer patients receiving stem cell transplants, potentially creating health problems for the recipients. Among the concerns are heart damage, graft-versus-host disease and possible new leukemias.

Read more

Yale Cancer Center researchers investigate inducing “synthetic lethality” in two blood and bone cancers

In a clinical trial led by Yale Cancer Center (YCC) and Smilow Cancer Hospital, researchers aim to exploit DNA mutations in the treatment of two blood and bone marrow cancers, a different tacit than the more traditional approach of blunting or switching off genetic mutations linked to cancer

Read more

Yale Cancer Center study suggests new approaches needed to manage ibrutinib-related toxicities in CLL patients

New findings by Yale Cancer Center (YCC) and Smilow Cancer Hospital researchers show that as the use of the drug ibrutinib climbs in patients with chronic lymphocytic leukemia (CLL), so do the rates of patients who stop taking the drug.

Read more

Yale Cancer Center researchers show promising new treatment for patients with myelodysplastic syndromes

A new study by Yale Cancer Center (YCC) and Smilow Cancer Hospital researchers suggests that the drug venetoclax aids therapy for relapsed/refractory myelodysplastic syndromes, especially when paired with azacytidine.

Read more

Yale Cancer Center researchers show identifying type of chronic pain in adults with sickle cell disease may lead to better outcomes

Identifying the type of pain an adult with sickle cell disease (SCD) experiences may be useful in improving treatment, according to a new study by researchers at Yale Cancer Center (YCC) and Smilow Cancer Hospital.

Read more